Pulmonx Corporation

Pulmonx Corporation company information, Employees & Contact Information

Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.1 1. Criner G et al AM J Resp Crit Care Med 2018, Published on 22-May-2018 as 10.1164/rccm.201803-0590OC Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Company Details

Employees
294
Address
700 Chesapeake Drive,, Redwood City,ca 94063,united States
Phone
650-364-0400
Email
in****@****onx.com
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Redwood City, CA
Looking for a particular Pulmonx Corporation employee's phone or email?

Pulmonx Corporation Questions

News

Pulmonx Corporation Announces Leadership Transition and Preliminary Third Quarter 2025 Revenue Estimates - Quiver Quantitative

Pulmonx Corporation Announces Leadership Transition and Preliminary Third Quarter 2025 Revenue Estimates Quiver Quantitative

Pulmonx (Nasdaq: LUNG) reappoints Glen French as CEO; preliminary Q3 revenue ~$21.5M - Stock Titan

Pulmonx (Nasdaq: LUNG) reappoints Glen French as CEO; preliminary Q3 revenue ~$21.5M Stock Titan

Pulmonx Announces Management Transition and Preliminary - GlobeNewswire

Pulmonx Announces Management Transition and Preliminary GlobeNewswire

Pulmonx Reports Second Quarter 2025 Financial Results - Yahoo Finance

Pulmonx Reports Second Quarter 2025 Financial Results Yahoo Finance

Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025 - GlobeNewswire

Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025 GlobeNewswire

Oct. 29, 2025: Pulmonx to Release Third Quarter Results; Webcast and Conference Call Available - Stock Titan

Oct. 29, 2025: Pulmonx to Release Third Quarter Results; Webcast and Conference Call Available Stock Titan

Pulmonx Corporation Announces Third Quarter 2025 Financial Results Release and Conference Call Details - Quiver Quantitative

Pulmonx Corporation Announces Third Quarter 2025 Financial Results Release and Conference Call Details Quiver Quantitative

Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers - Business Wire

Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers Business Wire

Pulmonx Reports First Quarter 2025 Financial Results - Yahoo Finance

Pulmonx Reports First Quarter 2025 Financial Results Yahoo Finance

Leading Lung Disease Treatment Company Pulmonx Showcases Growth Story at Major Healthcare Conference - Stock Titan

Leading Lung Disease Treatment Company Pulmonx Showcases Growth Story at Major Healthcare Conference Stock Titan

Pulmonx to Participate in September Investor Conferences - GlobeNewswire

Pulmonx to Participate in September Investor Conferences GlobeNewswire

Zephyr Endobronchial Valves One Step Closer to FDA Approval - respiratory-therapy.com

Zephyr Endobronchial Valves One Step Closer to FDA Approval respiratory-therapy.com

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial - Business Wire

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial Business Wire

Lung Disease Treatment Leader Pulmonx (LUNG) Sets Two Major Investor Conference Appearances in September - Stock Titan

Lung Disease Treatment Leader Pulmonx (LUNG) Sets Two Major Investor Conference Appearances in September Stock Titan

Pulmonx Corp (LUNG) Q2 2025 Earnings Call Highlights: Strong International Growth Amid US Challenges - Yahoo Finance

Pulmonx Corp (LUNG) Q2 2025 Earnings Call Highlights: Strong International Growth Amid US Challenges Yahoo Finance

Pulmonx Zephyr EBV Benefits Emphysema Patients - respiratory-therapy.com

Pulmonx Zephyr EBV Benefits Emphysema Patients respiratory-therapy.com

Jaeger™ and Pulmonx Announce Strategic Partnership to Integrate Data Qualification Capabilities into SentrySuite™ - PR Newswire

Jaeger™ and Pulmonx Announce Strategic Partnership to Integrate Data Qualification Capabilities into SentrySuite™ PR Newswire

What Makes Pulmonx (LUNG) a New Buy Stock - Yahoo Finance

What Makes Pulmonx (LUNG) a New Buy Stock Yahoo Finance

Pulmonx Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Pulmonx Second Quarter 2025 Earnings: Beats Expectations Yahoo Finance

Pulmonx Corp (LUNG) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... - Yahoo Finance

Pulmonx Corp (LUNG) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... Yahoo Finance

Pulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ... - Yahoo Finance

Pulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ... Yahoo Finance

Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema - Business Wire

Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema Business Wire

Pulmonx Acquires Assets of Aeris Therapeutics - respiratory-therapy.com

Pulmonx Acquires Assets of Aeris Therapeutics respiratory-therapy.com

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates - Nasdaq

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates Nasdaq

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema - The Globe and Mail

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema The Globe and Mail

Pulmonx at Goldman Sachs Conference: Strategic Growth Insights - Investing.com

Pulmonx at Goldman Sachs Conference: Strategic Growth Insights Investing.com

Pulmonx Launches Chartis Tablet for Zephyr EBV Therapy - respiratory-therapy.com

Pulmonx Launches Chartis Tablet for Zephyr EBV Therapy respiratory-therapy.com

Zephyr Valve for COPD: Purpose, Benefits, Risks, and Procedure - Healthline

Zephyr Valve for COPD: Purpose, Benefits, Risks, and Procedure Healthline

Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward - simplywall.st

Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward simplywall.st

Piper Sandler downgrades Pulmonx stock to Neutral on growth concerns - Investing.com

Piper Sandler downgrades Pulmonx stock to Neutral on growth concerns Investing.com

Hackensack Meridian JFK Advanced Lung and Airway Center is the Second Medical Center in the United States to Separate the Fissure Robotically and Then Place the Valve During the Same Surgery - Hackensack Meridian Health

Hackensack Meridian JFK Advanced Lung and Airway Center is the Second Medical Center in the United States to Separate the Fissure Robotically and Then Place the Valve During the Same Surgery Hackensack Meridian Health

Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valves, a Revolutionary Treatment Option for Patients with Severe Emphysema/COPD - Business Wire

Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valves, a Revolutionary Treatment Option for Patients with Severe Emphysema/COPD Business Wire

Pulmonx stock downgraded at Piper despite Q2 beat (LUNG) - Seeking Alpha

Pulmonx stock downgraded at Piper despite Q2 beat (LUNG) Seeking Alpha

Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent

Rockford Register Star: Local News, Politics & Sports in Rockford, IL FinancialContent

Pulmonx Corporation Reports Q2 2025 Financial Growth - TipRanks

Pulmonx Corporation Reports Q2 2025 Financial Growth TipRanks

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way? - simplywall.st

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way? simplywall.st

Pulmonx Corporation’s Earnings Call: Mixed Sentiment Amid Growth - TipRanks

Pulmonx Corporation’s Earnings Call: Mixed Sentiment Amid Growth TipRanks

Pulmonx Closing in On Approval for Valve to Treat Emphysema - Medical Device and Diagnostic industry

Pulmonx Closing in On Approval for Valve to Treat Emphysema Medical Device and Diagnostic industry

symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast CNN

The Prognosis For Pulmonx Corporation (NASDAQ:LUNG) - Seeking Alpha

The Prognosis For Pulmonx Corporation (NASDAQ:LUNG) Seeking Alpha

Pulmonx treats first patient in AeriSeal trial - MassDevice

Pulmonx treats first patient in AeriSeal trial MassDevice

Shareholders May Not Overlook Pulmonx Insiders Selling US$670k In Stock - simplywall.st

Shareholders May Not Overlook Pulmonx Insiders Selling US$670k In Stock simplywall.st

Inside INdiana Business - FinancialContent

Inside INdiana Business FinancialContent

Analysts Have Lowered Expectations For Pulmonx Corporation (NASDAQ:LUNG) After Its Latest Results - 富途牛牛

Analysts Have Lowered Expectations For Pulmonx Corporation (NASDAQ:LUNG) After Its Latest Results 富途牛牛

FDA approves Pulmonx’s severe emphysema device - Fierce Biotech

FDA approves Pulmonx’s severe emphysema device Fierce Biotech

Pulmonx raises $65M to market its lung valve implant worldwide - Fierce Biotech

Pulmonx raises $65M to market its lung valve implant worldwide Fierce Biotech

After scrapped IPO, Pulmonx raises $66M to back minimally invasive emphysema valve - BioWorld MedTech

After scrapped IPO, Pulmonx raises $66M to back minimally invasive emphysema valve BioWorld MedTech

Zephyr Valve Implants Lead to Significant Improvement In Lung Function, Quality Of Life - Lung Disease News

Zephyr Valve Implants Lead to Significant Improvement In Lung Function, Quality Of Life Lung Disease News

UAB Emphysema Patient Has Good Result From Experimental One-Way Valve Procedure | Newswise - Newswise

UAB Emphysema Patient Has Good Result From Experimental One-Way Valve Procedure | Newswise Newswise

One-way valves to treat severe emphysema - Medical Xpress

One-way valves to treat severe emphysema Medical Xpress

Pulmonx (NASDAQ:LUNG) Shares Up 0.6% – Here’s Why - Defense World

Pulmonx (NASDAQ:LUNG) Shares Up 0.6% – Here’s Why Defense World

Top Pulmonx Corporation Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant